Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HydroPol is a combination pharmaceutical product typically formulated as an otic or ophthalmic suspension. It contains **hydrocortisone**, a corticosteroid with anti-inflammatory and antipruritic properties, and **polymyxin B sulfate**, a polypeptide antibiotic effective against Gram-negative bacteria, particularly *Pseudomonas aeruginosa*. The mechanism of action involves hydrocortisone binding to cytoplasmic glucocorticoid receptors, leading to the inhibition of inflammatory mediators and the reduction of edema and capillary permeability. Polymyxin B acts by binding to phospholipids in the bacterial cytoplasmic membrane, disrupting its integrity and causing leakage of intracellular components, which results in bactericidal activity. It is primarily indicated for the treatment of superficial bacterial infections of the external auditory canal (otitis externa) or ocular structures when a steroid is also required to manage inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrocortisone + polymyxin b (Polfa Tarchomin).